Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

Lignende værker

• Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
  af: Platz, Anton, et al.
  Udgivet: (2007)
• Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
  af: Falkenius, Johan, et al.
  Udgivet: (2017)
• AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
  af: Das, Ishani, et al.
  Udgivet: (2020)
• Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
  af: Das, Ishani, et al.
  Udgivet: (2020)
• Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
  af: Azimi, Alireza, et al.
  Udgivet: (2017)